Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Clinical trial NCT04126200 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04126200
- Sponsor
- GlaxoSmithKline
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-07
- Primary completion
- 2025-04-17
- Enrollment
- 208
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.